Home  >  Research  >  Labs  >  Cancer Program  >  CANCER EPIGENETICS

RESEARCH OVERVIEW

The Cancer Epigenetics Laboratory is a multidisciplinary group that focuses on the development of novel approaches to target cancers that are currently refractory to treatment and associated to poor outcome, such as triple negative breast cancers and serious ovarian cancers. At present, there are no targeted approaches to combat these tumors, with chemotherapy and radiation the only treatment options. The laboratory generates novel functionalised molecules able to specifically target these tumors with minimal toxicity to normal cells. Our emphasis is in advanced stage metastatic tumors, which quasi invariably develop resistance. Ultimately we wish to revert the behaviour of metastatic cells by sensitising these treatment resistant tumors to chemotherapy regimes.

The lab deploys state-of-the art precision medicine tools to specifically re-engineer the genome and the epigenome of cancer cells, to restore mitotically hereditable (normal-like) features. Tools currently employed by the lab members include artificial genome engineering proteins (e.g made of zinc fingers, CRISPR/dCas9 backbones) attached to a library of effector domains for epigenomic editing.

The lab has patented and developed interference peptide technology, small synthetic and functionalised cell-penetrating peptides programmed to inhibit oncogenic transcription factors overexpressed in metastatic cells. By blocking or inhibiting essential protein-protein interactions we promote potent and selective apoptosis in metastatic breast cancer cells while sensitizing these tumors to chemotherapy regimes. Lastly, we collaborate with nanotechnology investigators (S. Iyer, UWA & Leaf Huang, UNC) to encapsulate these agents using targeted nanoparticles.

Associate Professor Pilar Blancafort

Associate Professor Pilar Blancafort

Cancer Epigenetics (Program Head - Cancer)

Read more

LATEST NEWS

Perkins secures biobanking grants to answer important questions in future research

The McGowan Government recently announced that the Harry Perkins Institute will receive two of the 16 grants totalling more than $1.5 million to support Western Australian biobanks. Congratulations to both Professor Grant Morahan who is Head of the Perkins' Centre for Diabetes Research, and Dr Louise Winteringham who leads the…

Read More

Interview with Prof Peter Leedman AO: Bee venom to treat cancer paid for by Australia’s biggest charity ride

An inspiring chat with Director at Harry Perkins Institute of Medical Research, Professor Peter Leedman AO, with The West's Ben O'Shea. Prof Leedman speaks about the wonderful MACA Cancer 200 Ride for Research, an annual two-day 200km charity bike ride event. He speaks of the incredible partnerships, donors, and supporters…

Read More

New treatment discovery for rare eye cancer

An unusual and often fatal form of eye melanoma shows early response to new combination of treatments. New discoveries in treatments are all about improved health outcomes for people who have diseases like cancer, and providing them with more time with families.   Thanks to the ongoing support of donors…

Read More

I'M LOOKING FOR

RESEARCH PROJECTS

TEAM MEMBERS

PUBLICATIONS